Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses ...
The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...
The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
2d
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...
Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...
Patients living with emphysema experience shortness of breath because areas within the lungs are diseased and are holding trapped air (hyperinflation of the lung). This makes it difficult to inhale ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...
AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback